Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomised, double-blind, placebo-controlled study _ PROSTASICKLE

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522005-38-00

Enrollment

144

Registered

2026-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell anaemia with vaso-occlusive crisis

Brief summary

Mean opioid consumption in morphine equivalent mg/day over the 28 days following randomization

Interventions

DRUGsolution à diluer pour perfusion

DRUGGlucose 5 % Fresenius Kabi

DRUGsolution pour perfusion

DRUGILOPROST ZENTIVA 100 microgrammes/mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean opioid consumption in morphine equivalent mg/day over the 28 days following randomization	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 10, 2026